

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

LASCPC-01

RRID:CVCL_UE17

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3356, RRID:CVCL_UE17

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_UE17

Proper Citation: ATCC Cat# CRL-3356, RRID:CVCL_UE17

Description: Cell line LASCPC-01 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate adenocarcinoma with neuroendocrine differentiation

Defining Citation: [PMID:27050099](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LASCPC-01

Cross References: ATCC:CRL-3356, cancercellines:CVCL_UE17, GEO:GSM2050760, Progenetix:CVCL_UE17, Wikidata:Q95981291

ID: CVCL_UE17

Vendor: ATCC

Catalog Number: CRL-3356

Record Creation Time: 20220427T220717+0000

Record Last Update: 20260905T181008+0000

Ratings and Alerts

No rating or validation information has been found for LASCPC-01.

No alerts have been found for LASCPC-01.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. *Cancer discovery*, 16(4), 760.

Sulsenti R, et al. (2024) Intracellular Osteopontin Promotes the Release of TNF?? by Mast Cells to Restrain Neuroendocrine Prostate Cancer. *Cancer immunology research*, 12(9), 1147.

Liu YN, et al. (2024) Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer. *Molecular oncology*.

Sandor LF, et al. (2024) De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis. *Cell reports*, 43(3), 113936.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Zhang A, et al. (2023) Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. *Cancer research communications*, 3(11), 2358.